外周T细胞淋巴瘤-话题@MedSci

#外周T细胞淋巴瘤#

32篇内容 | 3482人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1312209, encodeId=04f1131220962, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, objectType=article, longId=138647, objectId=e39113864ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39113864ec6, replyNumber=0, likeNumber=81, createdTime=2018-05-21, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39113864ec6, moduleTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e39113864ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312208, encodeId=84a1131220854, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, objectType=article, longId=131784, objectId=6781131e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781131e84a3, replyNumber=0, likeNumber=82, createdTime=2018-03-09, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781131e84a3, moduleTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781131e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312207, encodeId=6a03131220ec4, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？, objectType=article, longId=130749, objectId=b8ba130e490e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ba130e490e, replyNumber=0, likeNumber=86, createdTime=2018-02-28, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ba130e490e, moduleTitle=Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ba130e490e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312206, encodeId=0c6213122063a, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=张会来教授：外周T细胞淋巴瘤和NK/T细胞淋巴瘤的研究进展, objectType=article, longId=124109, objectId=73a712410935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73a712410935, replyNumber=0, likeNumber=66, createdTime=2017-12-22, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73a712410935, moduleTitle=张会来教授：外周T细胞淋巴瘤和NK/T细胞淋巴瘤的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73a712410935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312205, encodeId=cfb4131220573, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究, objectType=article, longId=120900, objectId=190612090080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=190612090080, replyNumber=0, likeNumber=43, createdTime=2017-11-22, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=190612090080, moduleTitle=【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=190612090080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312204, encodeId=45391312204b9, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=2016西达本胺治疗外周T细胞淋巴瘤中国专家共识发布, objectType=article, longId=76387, objectId=42a7e638770, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42a7e638770, replyNumber=0, likeNumber=81, createdTime=2016-09-02, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42a7e638770, moduleTitle=2016西达本胺治疗外周T细胞淋巴瘤中国专家共识发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42a7e638770)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=西达本胺治疗外周T细胞淋巴瘤中国专家共识（2016版）共识发布, objectType=article, longId=68785, objectId=6c5668e8555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c5668e8555, replyNumber=0, likeNumber=80, createdTime=2016-05-22, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c5668e8555, moduleTitle=西达本胺治疗外周T细胞淋巴瘤中国专家共识（2016版）共识发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c5668e8555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312202, encodeId=439113122024d, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=招募患者：普拉曲沙治疗复发或难治性外周T细胞淋巴瘤的有效性和安全性的临床研究, objectType=article, longId=56017, objectId=7e135601ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e135601ed5, replyNumber=0, likeNumber=78, createdTime=2015-09-11, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e135601ed5, moduleTitle=招募患者：普拉曲沙治疗复发或难治性外周T细胞淋巴瘤的有效性和安全性的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e135601ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312201, encodeId=faa013122015b, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=Lancet Haematology：硼替佐米联合帕比司他治疗复发性或难治性外周T细胞淋巴瘤, objectType=article, longId=53073, objectId=5090530e3a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5090530e3a5, replyNumber=0, likeNumber=83, createdTime=2015-07-10, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5090530e3a5, moduleTitle=Lancet Haematology：硼替佐米联合帕比司他治疗复发性或难治性外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5090530e3a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312200, encodeId=11f2131220097, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, objectTitle=JCO：分子图谱有助于外周T细胞淋巴瘤分类, objectType=article, longId=22124, objectId=5f662212409, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f662212409, replyNumber=0, likeNumber=80, createdTime=2013-07-28, rootId=0, userName=xlxchina, userId=570f404, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f662212409, moduleTitle=JCO：分子图谱有助于外周T细胞淋巴瘤分类, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f662212409)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

外周T细胞淋巴瘤

2020-05-29

xlxchina

#外周T细胞淋巴瘤#

Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！

2018-05-21

xlxchina

#外周T细胞淋巴瘤#

Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性

2018-03-09

xlxchina

#外周T细胞淋巴瘤#

Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？

2018-02-28

xlxchina

#外周T细胞淋巴瘤#

张会来教授：外周T细胞淋巴瘤和NK/T细胞淋巴瘤的研究进展

2017-12-22

xlxchina

#外周T细胞淋巴瘤#

【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究

2017-11-22

xlxchina

#外周T细胞淋巴瘤#

2016西达本胺治疗外周T细胞淋巴瘤中国专家共识发布

2016-09-02

xlxchina

#外周T细胞淋巴瘤#

西达本胺治疗外周T细胞淋巴瘤中国专家共识（2016版）共识发布

2016-05-22

xlxchina

#外周T细胞淋巴瘤#

招募患者：普拉曲沙治疗复发或难治性外周T细胞淋巴瘤的有效性和安全性的临床研究

2015-09-11

xlxchina

#外周T细胞淋巴瘤#

Lancet Haematology：硼替佐米联合帕比司他治疗复发性或难治性外周T细胞淋巴瘤

2015-07-10

xlxchina

#外周T细胞淋巴瘤#

JCO：分子图谱有助于外周T细胞淋巴瘤分类

2013-07-28